RankAlpha logo
Back to Rankings

ETON

EtonC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is that Eton is proving its rare-disease commercial model can compound: Q1 showed 73% product-sales growth, positive adjusted EBITDA, positive operating cash flow, and a higher revenue outlook, while DESMODA and HEMANGEOL add fresh commercial legs. If second-half launch traction and July/2H26 development milestones land, the market can support a higher multiple on a more diversified revenue base.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.5.
What can break
Adjusted gross margin fell to 67% in Q1 2026 from 69% a year earlier, with the company citing margin-dilutive INCRELEX ex-U.S. sales and prior-year licensing mix; that limits how much of the revenue beat drops through. [#SEC-8K-2026-05-14]
Momentum
90
Value
56
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $37.00 · Bear $24.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $46.70
Why
Momentum90 · Δ7d +4.5
Value56 · Δ7d -0.4
Sentiment20 · Δ7d -13.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
+3.7
Value
56
39% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-1.0
Sentiment
20
34% active weight
Current posture
7d trendSoftening
Δ7d
-13.5
Δ21d
-14.5
Why this grade

Composite grade C. Momentum 90.1 / Value 56.5 / Sentiment 19.9

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.16B
Beta
1.20
Shares Out
27.39M
P/E (TTM) · Derived
-247.5
P/S (TTM)
6.38
P/FCF (TTM)
34.80
Rev YoY
+40.4%
EPS YoY
-184.3%
Gross Margin
+54.8%
Op Margin
-3.8%
Net Debt
$5.14M
Current Ratio
1.21
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology